Skip to main content

International Therapeutics Licenses RNAi Quantification Product to Rosetta

NEW YORK, Sept. 28 (GenomeWeb News) - International Therapeutics has granted to Rosetta Inpharmatics a worldwide nonexclusive license to its ProxiQuant technology for research and development applications, IT said today.

 

ProxiQuant is an enzymatic application that enables stoichiometric generation of surrogate DNA targets from primary RNAi molecules in biological samples, IT said. As opposed to RT-PCR, ProxiQuant uses ligases to create larger DNA molecules from smaller RNAi, which can then be quantified using several methods.

 

Financial details of the agreement were not disclosed.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.